公开(公告)号：US12070453B2

公开(公告)日：2024-08-27

申请号：US16318905

申请日：2017-07-19

申请人： Amicus Therapeutics, Inc.

发明人： Jeff Castelli

IPC分类号： A61K31/445 ,  A61K31/45 ,  A61K31/7008

CPC分类号： A61K31/445 ,  A61K31/45 ,  A61K31/7008

摘要： Provided are dosing regimens for the treatment of Fabry disease in a patient. Certain methods relate to the treatment of ERT-experienced or ERT-nave Fabry patients. Certain methods comprise administering to the patient about 123 mg free base equivalent of migalastat for improving left ventricular mass and/or improving podocyte globotriaosylceramide.

公开(公告)号：US12005098B2

公开(公告)日：2024-06-11

申请号：US16461977

申请日：2017-11-23

申请人： PEPSIS LIMITED

发明人： John Hunter ,  Rosemary Waring

IPC分类号： C12Q1/40 ,  A23K10/30 ,  A23K10/38 ,  A23K20/158 ,  A23K20/189 ,  A23K20/20 ,  A23K20/24 ,  A23K50/20 ,  A61K9/14 ,  A61K31/122 ,  A61K31/19 ,  A61K31/198 ,  A61K31/20 ,  A61K31/351 ,  A61K31/352 ,  A61K31/366 ,  A61K31/7008 ,  A61K33/06 ,  A61K33/24 ,  A61K36/185 ,  A61K36/45 ,  A61K36/889 ,  A61K38/47 ,  A61K45/06 ,  C12Q1/34

CPC分类号： A61K38/47 ,  A23K10/30 ,  A23K10/38 ,  A23K20/158 ,  A23K20/189 ,  A23K20/24 ,  A23K20/30 ,  A23K50/20 ,  A61K9/14 ,  A61K31/122 ,  A61K31/19 ,  A61K31/198 ,  A61K31/20 ,  A61K31/351 ,  A61K31/352 ,  A61K31/366 ,  A61K31/7008 ,  A61K33/06 ,  A61K33/24 ,  A61K36/185 ,  A61K36/45 ,  A61K36/889 ,  A61K45/06 ,  C12Q1/34 ,  C12Q1/40 ,  C12Y302/01001 ,  C12Y302/01002 ,  C12Y302/0108 ,  A23V2250/00 ,  A23V2250/1578 ,  A23V2250/1586 ,  A23V2250/1612 ,  A23V2250/1878 ,  A23V2250/21 ,  Y02P60/87 ,  A61K33/06 ,  A61K2300/00 ,  A61K33/24 ,  A61K2300/00 ,  A61K31/352 ,  A61K2300/00 ,  A61K31/198 ,  A61K2300/00 ,  A61K31/7008 ,  A61K2300/00 ,  A61K31/122 ,  A61K2300/00 ,  A61K36/185 ,  A61K2300/00 ,  A61K36/45 ,  A61K2300/00

摘要： The present invention relates to compositions comprising: malt extract including a plurality of enzymatically active enzymes including at least fructanase and amylase; one or more medium-chain triglycerides (MCTs) and/or at least one biologically acceptable metal component and use of those compositions as veterinary and human medicaments.

公开(公告)号：US11969508B2

公开(公告)日：2024-04-30

申请号：US18310549

申请日：2023-05-02

申请人： WANKA TANKA LTD.

发明人： Amnon Vardi

IPC分类号： A61K9/70 ,  A61K31/10 ,  A61K31/164 ,  A61K31/7008 ,  A61K31/737 ,  A61K36/38 ,  A61K38/39 ,  A61K47/10 ,  A61K47/14 ,  A61P19/02

CPC分类号： A61K9/7084 ,  A61K31/10 ,  A61K31/164 ,  A61K31/7008 ,  A61K31/737 ,  A61K36/38 ,  A61K38/39 ,  A61K47/10 ,  A61K47/14 ,  A61P19/02

摘要： A plastic material for extended release of a bio-active agent, the plastic material comprising a structural polymer, at least one bio-active ingredient embedded within the structural polymer as solid islands, a liquid binding material embedded within the structural polymer as granules, and a carrier liquid absorbed within the liquid-absorbent material. The carrier liquid may be sufficiently non-compatible with the structural polymer so that at least a portion of the carrier liquid is released from the liquid-absorbent material through the structural polymer to an outer surface of the plastic material over a period of time, such as a week or more, a month or more, or about three months. The bio-active agent comprised in the at least one bio-active ingredient may be sufficiently soluble in the carrier liquid at room or body temperature so that the carrier liquid released to the outer surface comprises the bio-active agent in solution.

公开(公告)号：US20240091243A1

公开(公告)日：2024-03-21

申请号：US18261592

申请日：2022-01-29

申请人： Ameer E. HASSAN ,  Yousef Hasan Ahmad KHALILI

发明人： Ameer E. HASSAN ,  Yousef Hasan Ahmad KHALILI

IPC分类号： A61K31/7008 ,  A61K31/07 ,  A61K31/375 ,  A61K31/519 ,  A61K31/593 ,  A61K33/30 ,  A61P31/14

CPC分类号： A61K31/7008 ,  A61K31/07 ,  A61K31/375 ,  A61K31/519 ,  A61K31/593 ,  A61K33/30 ,  A61P31/14

摘要： The present disclosure relates to compounds and methods for preventing infection, symptoms, or sequelae resulting from viral infection, including influenza infection, rhinovirus infection, or betacoronavirus infection, such as human coronaviruses such as SARS coronaviruses, MERS coronaviruses, and COVID-19, including Acute Respiratory Distress Syndrome (ARDS) associated with the viral infection.

公开(公告)号：US20240024310A1

公开(公告)日：2024-01-25

申请号：US18176533

申请日：2023-03-01

申请人： Otsuka Pharmaceutical Co., Ltd.

发明人： Tetsuro Kikuchi ,  Taro Iwamoto ,  Tsuyoshi Hirose

IPC分类号： A61K31/496 ,  A61K31/19 ,  A61K31/195 ,  A61K31/425 ,  A61K31/4704 ,  A61K31/497 ,  A61K31/55 ,  A61K31/7008 ,  A61K33/00 ,  A61K33/14 ,  A61K45/06 ,  A61K31/357 ,  A61K31/4015 ,  A61K31/423 ,  A61K31/53 ,  A61K31/5513

CPC分类号： A61K31/496 ,  A61K31/19 ,  A61K31/195 ,  A61K31/425 ,  A61K31/4704 ,  A61K31/497 ,  A61K31/55 ,  A61K31/7008 ,  A61K33/00 ,  A61K33/14 ,  A61K45/06 ,  A61K31/357 ,  A61K31/4015 ,  A61K31/423 ,  A61K31/53 ,  A61K31/5513

摘要： The pharmaceutical composition of the present invention comprises a carbostyril derivative which is a dopamine-serotonin system stabilizer and a mood stabilizer in a pharmaceutically acceptable carrier. The carbostyril derivative may be aripiprazole or a metabolite thereof. The mood stabilizer may include but is not limited to lithium, valproic acid, divalproex sodium, carbamazapine, oxcarbamazapine, zonisamide, lamotragine, topiramate, gabapentin, levetiracetam or clonazepam. These compositions are used to treat patients with mood disorders, particularly bipolar disorder with or without psychotic features, mania or mixed episodes. Methods are provided for separate administration of a carbostyril derivative and a mood stabilizer to a patient with a mood disorder.

公开(公告)号：US20230398178A1

公开(公告)日：2023-12-14

申请号：US18334253

申请日：2023-06-13

申请人： Massachusetts Institute of Technology

发明人： Katharina Ribbeck ,  Laura L. Kiessling ,  Caroline Andrea Werlang ,  Spencer D. Brucks ,  Liubov Yakovlieva ,  Kelsey Morgan Wheeler

IPC分类号： A61K38/17 ,  A61K31/7004 ,  A61K35/747 ,  A61K31/4164 ,  A61K47/64 ,  A61P31/04 ,  A61K31/7008 ,  A61K47/58

CPC分类号： A61K38/1735 ,  A61K31/7004 ,  A61K35/747 ,  A61K31/4164 ,  A61K47/64 ,  A61P31/04 ,  A61K31/7008 ,  A61K47/58

摘要： Methods of treating or preventing a vaginal infection of Gardnerella vaginalis in a subject involve administering to the subject an effective amount of a composition. The composition can include one or more of galactose, D-fucose, or mucin 5B. The composition can include one or more of galactose, N-acetyl D-galactosamine, N-acetyl D-glucosamine, D-fucose, or mucin 5B bonded to a surface, such as a polymer surface.

公开(公告)号：US11833164B2

公开(公告)日：2023-12-05

申请号：US16987884

申请日：2020-08-07

申请人： Amicus Therapeutics, Inc.

发明人： Elfrida Benjamin ,  Xiaoyang Wu

IPC分类号： A61K31/7008 ,  G16H50/20 ,  G16B20/20 ,  C12Q1/6883

CPC分类号： A61K31/7008 ,  C12Q1/6883 ,  G16B20/20 ,  G16H50/20 ,  C12Q2600/106 ,  C12Q2600/156

摘要： Provided are methods of treating a patient diagnosed with Fabry disease and methods of enhancing α-galactosidase A in a patient diagnosed with or suspected of having Fabry disease. Certain methods comprise administering to a patient a therapeutically effective dose of a pharmacological chaperone for α-galactosidase A, wherein the patient has a mutation in the nucleic acid sequence encoding α-galactosidase A. Also described are uses of pharmacological chaperones for the treatment of Fabry disease and compositions for use in the treatment of Fabry disease.

公开(公告)号：US11826343B2

公开(公告)日：2023-11-28

申请号：US18126551

申请日：2023-03-27

申请人： TULEX PHARMACEUTICALS INC.

发明人： Yu-Hsing Tu ,  Ashok Perumal ,  Kalyan Kathala ,  Romona Bhattacharya

IPC分类号： A61K31/25 ,  A61K31/235 ,  A61K31/7008 ,  A61K31/047 ,  A61K9/14 ,  A61K38/00 ,  A61K31/357 ,  A61K9/08 ,  A61K47/34 ,  A61K47/10 ,  A61J1/06 ,  A61J7/00 ,  A61K9/00 ,  A61K47/69 ,  A61P25/00 ,  A61K9/48 ,  A61K47/20 ,  A61K47/26 ,  A61K47/36 ,  A61K47/42

CPC分类号： A61K31/357 ,  A61J1/06 ,  A61J7/0023 ,  A61J7/0046 ,  A61J7/0053 ,  A61K9/0053 ,  A61K9/08 ,  A61K9/14 ,  A61K9/48 ,  A61K31/047 ,  A61K31/235 ,  A61K31/25 ,  A61K31/7008 ,  A61K38/005 ,  A61K47/10 ,  A61K47/20 ,  A61K47/26 ,  A61K47/34 ,  A61K47/36 ,  A61K47/42 ,  A61K47/6939 ,  A61P25/00

摘要： Compositions are provided for the liquid oral administration of topiramate and its salts. The invention further provides methods for treating diseases and disorders using the compositions.

公开(公告)号：US20230329313A1

公开(公告)日：2023-10-19

申请号：US18302171

申请日：2023-04-18

申请人： Florida Research Group, LLC

发明人： Kotha SEKHARAM

IPC分类号： A61K31/7008 ,  A61K9/00 ,  A23L29/262 ,  A23K20/121 ,  A23K20/158 ,  A23P30/10 ,  A61K47/38 ,  A61K47/36 ,  A61K31/122 ,  A23L29/10 ,  A23L29/00 ,  A23K40/20 ,  A61K47/26 ,  A23K20/163 ,  A61K31/737 ,  A61K47/46 ,  A61K47/12 ,  A23P20/20

CPC分类号： A23P30/10 ,  A23K20/121 ,  A23K20/158 ,  A23K20/163 ,  A23K40/20 ,  A23L29/04 ,  A23L29/10 ,  A23L29/262 ,  A23P20/20 ,  A61K9/0056 ,  A61K31/122 ,  A61K31/7008 ,  A61K31/737 ,  A61K47/12 ,  A61K47/26 ,  A61K47/36 ,  A61K47/38 ,  A61K47/46

摘要： The invention relates to the field of orally administrable pharmaceutical and nutritional supplement dosage form; in particular, units in the form of an edible mass as chews for animals as well as for humans.

公开(公告)号：US20230190852A1

公开(公告)日：2023-06-22

申请号：US18113370

申请日：2023-02-23

申请人： Unigen, Inc.

发明人： Lidia Alfaro Brownell ,  Min Chu ,  Mei-Feng Hong ,  Eu-Jin Hyun ,  Qi Jia ,  Ping Jiao ,  Young-Chul Lee ,  Mesfin Yimam

IPC分类号： A61K36/605 ,  A61K36/48 ,  A61K36/534 ,  A61K31/05 ,  A61K31/352 ,  A61K31/353 ,  A61K31/7008 ,  A61K31/7028 ,  A61K31/7034

CPC分类号： A61K36/605 ,  A61K36/48 ,  A61K36/534 ,  A61K31/05 ,  A61K31/352 ,  A61K31/353 ,  A61K31/7008 ,  A61K31/7028 ,  A61K31/7034

摘要： The present disclosure provides mixtures of prenylated flavonoids, stilbenes, or both with flavans or curcuminoids or both capable of modulating joint inflammation, joint pain, joint stiffness, cartilage degradation, or improving mobility, range of motion, flexibility, joint physical function, or any combination thereof. Such a mixture of prenylated flavonoids, stilbenes, or both with flavans or curcuminoids or both can optionally be used in combination with other joint management agents, such as non-steroidal anti-inflammatory agents/analgesics, COX/LOX inhibiting agents, glucosamine compounds, neuropathic pain relief agents, or the like.